Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Expanded_access × osimertinib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

EGFR T790M Mutation Positive NSCLC 1

Interventions

elotuzumab 4 dabrafenib 4 trametinib 3 pembrolizumab 3 nilotinib 3 midostaurin 3 fludarabine phosphate 3 fludarabine 3 Nivolumab 3 Ipilimumab 3 Everolimus 3 Cyclophosphamide 3 Amifampridine 3 veliparib 2 talimogene laherparepvec 2 regorafenib 2 gallium 68 PSMA-11 2 carbon-11 acetate 2 aldesleukin 2 Trabectedin 2 Suspensions 2 Powders 2 Panobinostat 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Lenalidomide 2 Dexamethasone 2 Crizotinib 2 Bortezomib 2 Axitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

AstraZeneca

No longer available

EGFR T790M Mutation Positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡